Class information for:
Level 1: OBLIMERSEN//G3139//ANTISENSE BCL 2

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
19375 508 41.1 86%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
441 3       TRAIL//SURVIVIN//APOPTOSIS 26474
306 2             TRAIL//SURVIVIN//APOPTOSIS 18497
19375 1                   OBLIMERSEN//G3139//ANTISENSE BCL 2 508

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 OBLIMERSEN authKW 423248 3% 54% 13
2 G3139 authKW 269359 2% 41% 11
3 ANTISENSE BCL 2 authKW 240432 1% 100% 4
4 BCL 2 authKW 236446 34% 2% 171
5 CT120 authKW 180324 1% 100% 3
6 GROWTH FACTOR DEPRIVATION THERAPY authKW 180324 1% 100% 3
7 EXPT ONCOL MOL PHARMACOL address 120216 0% 100% 2
8 GENASENSE authKW 120216 0% 100% 2
9 ALBERT E EIN MONTEFIORE CANC address 87425 1% 36% 4
10 BCL 2 ANTISENSE authKW 80139 1% 33% 4

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 5665 54% 0% 276
2 Hematology 3489 26% 0% 130
3 Medicine, Research & Experimental 211 9% 0% 44
4 Cell Biology 31 6% 0% 31
5 Urology & Nephrology 28 3% 0% 15
6 Pharmacology & Pharmacy 28 7% 0% 36
7 Pathology 13 2% 0% 11
8 Biophysics 12 3% 0% 15
9 Medical Laboratory Technology 10 1% 0% 5
10 Biotechnology & Applied Microbiology 9 3% 0% 17

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 EXPT ONCOL MOL PHARMACOL 120216 0% 100% 2
2 ALBERT E EIN MONTEFIORE CANC 87425 1% 36% 4
3 BONE MARROW TRANSPLANTAT CHILDREN ONCOL HA 60108 0% 100% 1
4 CANC ENVIRONM PETR POLLUTANTS 60108 0% 100% 1
5 CHILDRENS CANC LEUKEMIA STUDY GRP 60108 0% 100% 1
6 FRE 2141IFR 53 60108 0% 100% 1
7 GESELL MOL BIOTECHNOL 60108 0% 100% 1
8 MOL MED DRUG DEV XDVI CHEMOINFORMAT 60108 0% 100% 1
9 MORRIS CANC CLIN 60108 0% 100% 1
10 NCI COMPREHENS CANC CCC 60108 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 LEUKEMIA 5782 5% 0% 27
2 MEDICAL ONCOLOGY 4104 3% 0% 15
3 CLINICAL CANCER RESEARCH 2925 5% 0% 27
4 OLIGONUCLEOTIDES 2005 1% 1% 3
5 LEUKEMIA & LYMPHOMA 1761 3% 0% 15
6 IN VIVO 1496 2% 0% 8
7 BLOOD 1061 5% 0% 25
8 CELL GROWTH & DIFFERENTIATION 1059 1% 0% 5
9 HEMATOLOGY 978 1% 0% 4
10 INTERNATIONAL JOURNAL OF ONCOLOGY 891 2% 0% 12

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 OBLIMERSEN 423248 3% 54% 13 Search OBLIMERSEN Search OBLIMERSEN
2 G3139 269359 2% 41% 11 Search G3139 Search G3139
3 ANTISENSE BCL 2 240432 1% 100% 4 Search ANTISENSE+BCL+2 Search ANTISENSE+BCL+2
4 BCL 2 236446 34% 2% 171 Search BCL+2 Search BCL+2
5 CT120 180324 1% 100% 3 Search CT120 Search CT120
6 GROWTH FACTOR DEPRIVATION THERAPY 180324 1% 100% 3 Search GROWTH+FACTOR+DEPRIVATION+THERAPY Search GROWTH+FACTOR+DEPRIVATION+THERAPY
7 GENASENSE 120216 0% 100% 2 Search GENASENSE Search GENASENSE
8 BCL 2 ANTISENSE 80139 1% 33% 4 Search BCL+2+ANTISENSE Search BCL+2+ANTISENSE
9 4 HYDROXYPHENYL RETINAMIDE 60108 0% 100% 1 Search 4+HYDROXYPHENYL+RETINAMIDE Search 4+HYDROXYPHENYL+RETINAMIDE
10 A549 AND A549DDP CELL LINES 60108 0% 100% 1 Search A549+AND+A549DDP+CELL+LINES Search A549+AND+A549DDP+CELL+LINES

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 PATEL, MP , MASOOD, A , PATEL, PS , CHANAN-KHAN, AA , (2009) TARGETING THE BCL-2.CURRENT OPINION IN ONCOLOGY. VOL. 21. ISSUE 6. P. 516 -523 32 48% 41
2 COX, SL , (2004) OBLIMERSEN SODIUM. ONCOLYTIC, ANTISENSE OLIGONUCLEOTIDE, BCL2 EXPRESSION INHIBITOR..DRUGS OF THE FUTURE. VOL. 29. ISSUE 9. P. 877-881 19 90% 0
3 RUDIN, CM , KOZLOFF, M , HOFFMAN, PC , EDELMAN, MJ , KARNAUSKAS, R , TOMEK, R , SZETO, L , VOKES, EE , (2004) PHASE I STUDY OF G3139, A BCL-2 ANTISENSE OLIGONUCLEOTIDE, COMBINED WITH CARBOPLATIN AND ETOPOSIDE IN PATIENTS WITH SMALL-CELL LUNG CANCER.JOURNAL OF CLINICAL ONCOLOGY. VOL. 22. ISSUE 6. P. 1110-1117 24 53% 109
4 RUBENSTEIN, M , HOLLOWELL, CMP , GUINAN, P , (2011) EFFECTS OF BCL-2 SUPPRESSION BY ANTISENSE OLIGONUCLEOTIDES ON ADDITIONAL REGULATORS OF APOPTOSIS COMPENSATORY CHANGE IN NON-TARGETED PROTEIN EXPRESSION.IN VIVO. VOL. 25. ISSUE 5. P. 725-732 14 82% 2
5 CHABER, R , FISZER-MALISZEWSKA, L , NOWOROLSKA-SAUREN, D , KWASNICKA, J , WROBEL, G , CHYBICKA, A , (2013) THE BCL-2 PROTEIN IN PRECURSOR B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN.JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY. VOL. 35. ISSUE 3. P. 180-187 25 40% 1
6 KLASA, RJ , GILLUM, AM , KLEM, RE , FRANKEL, SR , (2002) OBLIMERSEN BCL-2 ANTISENSE: FACILITATING APOPTOSIS IN ANTICANCER TREATMENT.ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT. VOL. 12. ISSUE 3. P. 193 -213 30 35% 177
7 KIM, R , EMI, M , TANABE, K , TOGE, T , (2004) THERAPEUTIC POTENTIAL OF ANTISENSE BCL-2 AS A CHEMOSENSITIZER FOR CANCER THERAPY.CANCER. VOL. 101. ISSUE 11. P. 2491-2502 30 34% 68
8 ROM, J , VON MINCKWITZ, G , EIERMANN, W , SIEVERT, M , SCHLEHE, B , MARME, F , SCHUETZ, F , SCHARF, A , EICHBAUM, M , SINN, HP , ET AL (2008) OBLIMERSEN COMBINED WITH DOCETAXEL, ADRIAMYCIN AND CYCLOPHOSPHAMIDE AS NEO-ADJUVANT SYSTEMIC TREATMENT IN PRIMARY BREAST CANCER: FINAL RESULTS OF A MULTICENTRIC PHASE I STUDY.ANNALS OF ONCOLOGY. VOL. 19. ISSUE 10. P. 1698 -1705 17 52% 7
9 RUBENSTEIN, M , HOLLOWELL, CMP , GUINAN, P , (2012) DIFFERENTIATED PROSTATIC ANTIGEN EXPRESSION IN LNCAP CELLS FOLLOWING TREATMENT WITH BISPECIFIC ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST BCL-2 AND EGFR.MEDICAL ONCOLOGY. VOL. 29. ISSUE 2. P. 835-841 10 77% 3
10 GJERTSEN, BT , BREDHOLT, T , ANENSEN, N , VINTERMYR, OK , (2007) BCL-2 ANTISENSE IN THE TREATMENT OF HUMAN MALIGNANCIES: A DELUSION IN TARGETED THERAPY.CURRENT PHARMACEUTICAL BIOTECHNOLOGY. VOL. 8. ISSUE 6. P. 373-381 28 30% 14

Classes with closest relation at Level 1


Rank Class id link
1 35782 ALTERNOL//DELISHENG//AND TUMOR INVASION
2 640 MCL 1//BCL 2 FAMILY//BH3 MIMETIC
3 8759 FOLLICULAR LYMPHOMA//T1418//T1418 TRANSLOCATION
4 37421 BCL2L12//BCL2L12A//BRAIN TUMOR GENET MED
5 2407 ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT//ANTISENSE OLIGONUCLEOTIDES//ANTISENSE RESEARCH AND DEVELOPMENT
6 13947 P53//AREA BIOPATOL//BCL 2
7 15859 TAXOL//PACLITAXEL//BCL 2 PHOSPHORYLATION
8 27700 JOINT SERV BIOMARKER EVALUAT ONCOL//KI67 SCORE//LOCDIR
9 14363 GLUCOCORTICOID INDUCED APOPTOSIS//CORTIVAZOL//GLUCOCORTICOID RESISTANCE
10 3694 APOPTOSIS//HIGH MOLECULAR WEIGHT DNA FRAGMENTATION//ENDONUCLEASE

Go to start page